AAtlas Molecular Pharma
Atlas Molecular Pharma is a Spanish biotech spun off from CIC bioGUNE in 2015, developing first-in-class pharmacological chaperones via its proprietary Chassys platform to treat rare and ultra-rare metabolic diseases. Its lead candidate, ATL-001, targets congenital erythropoietic porphyria and has FDA Fast Track designation; the company is entering Phase I-II clinical trials. Headquartered at the Bizkaia Science and Technology Park (Derio, Spain), it has raised Series A funding led by Inveready.
SectorsBiotechnology, Rare Diseases, Drug Discovery, Pharmaceuticals
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
J
Joaquín Castilla
Founder & CTO
Ó
Óscar Millet
Founder & CSO
Global models 5
G
Global Blood Therapeutics
United States · www.gbt.com ↗
Developed small-molecule drugs that modulate/stabilize protein function to treat a rare genetic blood disease, mirroring Atlas's protein-stabilization chaperone approach.
$1.05BComparable
BBridgeBio Pharma
United States · www.bridgebio.com ↗
Platform biotech founding programs around genetically defined rare diseases and licensing/partnering assets, similar to Atlas's discovery-to-license model.
$434MComparable
CChinook Therapeutics
United States · www.chinooktx.com ↗
Precision-medicine biotech developing small-molecule and biologic therapies for rare kidney diseases, comparable rare-disease drug discovery model.
$286MComparable
UUltragenyx Pharmaceutical
United States · www.ultragenyx.com ↗
Biotech dedicated exclusively to therapies for rare and ultra-rare genetic diseases, the same target-patient-population strategy as Atlas.
$120MComparable
AAmicus Therapeutics
United States · www.amicusrx.com ↗
Pioneered pharmacological chaperone drugs that stabilize misfolded enzymes to treat lysosomal storage disorders, the closest direct model match to Atlas's Chassys platform.
$91MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 7
Open as list →
Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2022-02-01 | Series A (estimated) | €3M |
Inveready, CDTI, Ezten FCR (Grupo SPRI)
+3 more
|
News 2
Open as list →| Published | Article |
|---|---|
| 2026-01-15 |
Atlas Molecular Pharma closes a €3 million funding round led by Inveready to advance its clinical program in rare diseases ↗
Biotech Spain
2026-01-15 |
| 2024-05-28 |
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Congenital Erythropoietic Porphyria ↗
AseBio
2024-05-28 |